Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -29,613 | -165,673 | -103,175 | -55,463 | -29,281 |
| Depreciation Amortization | -16 | -1,348 | -1,278 | -1,041 | -667 |
| Accounts payable and accrued liabilities | 2,925 | 2,792 | 8,625 | 1,722 | -150 |
| Other Working Capital | -16,879 | 47,097 | 24,534 | 7,054 | 1,634 |
| Other Operating Activity | -1,031 | 3,931 | -3,380 | 1,807 | 1,924 |
| Operating Cash Flow | $-44,614 | $-113,201 | $-74,674 | $-45,921 | $-26,540 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 29,000 | 100,400 | 66,400 | 33,358 | 14,497 |
| PPE Investments | N/A | -91 | -91 | -68 | -49 |
| Investing Cash Flow | $29,000 | $100,309 | $66,309 | $33,290 | $14,448 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 108,115 | 65,086 | 65,287 | N/A | N/A |
| Financing Cash Flow | $108,115 | $65,086 | $65,287 | $N/A | $N/A |
| Beginning Cash Position | 86,018 | 33,824 | 33,824 | 33,824 | 33,824 |
| End Cash Position | 178,519 | 86,018 | 90,746 | 21,193 | 21,732 |
| Net Cash Flow | $92,501 | $52,194 | $56,922 | $-12,631 | $-12,092 |
| Free Cash Flow | |||||
| Operating Cash Flow | -44,614 | -113,201 | -74,674 | -45,921 | -26,540 |
| Capital Expenditure | N/A | -91 | -91 | -68 | -49 |
| Free Cash Flow | -44,614 | -113,292 | -74,765 | -45,989 | -26,589 |